Pro Medicus Moving On New Revenue Streams
Pro Medicus continues to invest heavily in R&D and, over the next 2-3 years, should generate revenue from new areas such as ophthalmology and cardiology.
Read More
At Pro Medicus, our aim is to deliver success for our customers’ practices. We are a leading provider of radiology information systems (RIS), Picture Archiving and Communication Systems (PACS) and advanced visualization solutions across the globe, with over 30 years experience helping our clients deliver first-rate patient care by enhancing and streamlining medical practice management. Our expertise is this client visualisation technology and the management of the supporting information. We do this by providing products and services that combine speed, scalability, stability and smarts to help eliminate administrative tasks and workarounds, optimise the efficiency of clinical and administrative staff and maximise profits.
Primary products for RIS include medical accounting, clinical reporting, appointments/scheduling and marketing/ management information applications. Our services cover workflow mapping and optimisation, network design and implementation, hardware sourcing and configuration and staff and management training. Everything we do is about providing seamless, integrated solutions in imaging IT.
We place strong emphasis on customer satisfaction by providing responsive, 24/7 service and support. This is reflected in the productive working relationships we’ve established with imaging centres, community hospitals and companies scaling from the smallest facility or department up to the largest hospital or enterprise.
Pro Medicus continues to invest heavily in R&D and, over the next 2-3 years, should generate revenue from new areas such as ophthalmology and cardiology.
Read More
The Neutral rating is maintained, as the broker feels the current company valuation is elevated. The target of $46 is maintained.
Read More
Citi initiates coverage on Pro Medicus with a Sell rating and a $45 target price.
Read More
While the broker increases the target price to $49.69 from $41.30, current prices are considered unsustainable in the short term.
Read More
UBS highlights Pro Medicus's radiology pipeline conversion over 6 years is significantly above UBS's estimate and suggests continuing momentum into the second half. Neutral rating is reaffirmed with a target of $32.
Read More
Pro Medicus has secured a long-term contract for $18m with a US based hospital system. Morgans' Add rating is maintained and the target price is increased to $35.02 from $33.32.
Read More